Rhythm Pharmaceuticals amended its exclusive license agreement with LG Chem for the oral MC4R agonist bivamelagon, lowering royalties to 1% and agreeing to $350 million in fixed payments over four years. To support this and its global commercialization efforts, Rhythm secured a $750 million term loan led by KKR’s HealthCare Royalty and Blackstone. This financial move aims to accelerate development and patient access to treatments for rare obesity diseases, reinforcing Rhythm's leadership in MC4R pathway therapies.
Rhythm Pharmaceuticals' recent amendment to its license agreement and financial arrangements provide context for readers following health sector developments. For readers following health sector stocks, here is Pluang's market snapshot as of Nov 03, 2026 06:32 WIB: out of 150 priced US health stocks, 54 rose and 94 fell. Notable movers include HIMS at USD 25.37 with a 0% Sell / 100% Buy order activity and a typical hold time of 23 days, RMD at USD 231.76 down 8.33% with a 52-day hold, and LQDA at USD 41.69 down 7.48% with 100% Sell order activity and a 4-day hold time.
ZYT officially introduced its Prax Drive System™, a commercial vehicle technology, partnering with leading Chinese truck makers like XCMG, Shacman, and Sinotruk. The system supports heavy trucks, buses, light trucks, and vans, with production underwa...
The Geely E2 (EX2) electric car has reached one million units sold globally within two years of its launch in October 2024, marking rapid market acceptance. It became the world's best-selling car in A&B segments in 2025 and topped sales charts in cou...
AI data centers are expanding beyond traditional land-based locations due to increasing power and space constraints. Companies like Aikido Technologies are exploring floating data centers powered by offshore wind, while Elon Musk's SpaceX plans to de...
Global Indemnity Group will postpone its third quarter 2026 earnings call originally scheduled for November 4 to January, when new CEO Jessica Buss will present her vision and priorities for the company. The company will still release its Q3 results ...
Lorraine Ben, former CEO of Lockheed Martin Canada, has joined Syntax Defence to provide expert counsel amid Canada's commitment to invest over half a trillion dollars in defence over the next decade. This includes $180 billion in procurement opportu...
